Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients withde novocoronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial-Reference-Cited by-同舟云学术

Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients withde novocoronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial

Published:2016-05-17 Issue:35 Volume:37 Page:2701-2709
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:Eur Heart J

Author:

Haude Michael,Ince Hüseyin,Abizaid Alexandre,Toelg Ralph,Lemos Pedro Alves,von Birgelen Clemens,Christiansen Evald Høj,Wijns William,Neumann Franz-Josef,Kaiser Christoph,Eeckhout Eric,Lim Soo Teik,Escaned Javier,Onuma Yoshinobu,Garcia-Garcia Hector M.,Waksman Ron

Funder

Biotronik AG

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/37/35/2701/17357111/ehw196.pdf

Reference24 articles.

1. Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease

2. Bioresorbable scaffolds: rationale, current status, challenges, and future

3. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials